Direct comparison
Centralized vs. Decentralized Clinical Trials
Compare centralized and decentralized clinical trial models on burden, site infrastructure, patient reach, and regulatory oversight, plus how to choose.
Side-by-side comparison
| Dimension | Centralized (Site-Based) Trial | Decentralized (DCT) Trial |
|---|---|---|
| Where study visits happen | Participants travel to a limited number of investigator sites for all or nearly all protocol procedures. | Some or all visits occur remotely: telehealth, local labs/imaging, home health providers, or the participant's own home. |
| Regulatory framework | Same IND/IDE, ICH GCP (E6(R3)), Common Rule/21 CFR 50, safety-reporting requirements. | Identical framework — FDA's Sept. 2024 final guidance applies existing rules to off-site activities, not a separate DCT pathway. |
| Site infrastructure required | Full on-site capacity at each site: exam space, IMP storage/pharmacy, phlebotomy/imaging, dedicated clinical staff. | Reduced per-site footprint, but requires a DtP-capable supply chain, Part 11-compliant remote data/eConsent tech, and a local/telehealth provider network. |
| Administrative burden | Concentrated and duplicated at each site: contracts, budgets, essential documents, scheduling per site. | Shifts substantially to sponsor-level vendor qualification and oversight of home-health, courier, and technology vendors. |
| Patient population reach | Limited to participants able to travel repeatedly to a site; can underrepresent rural/mobility-limited populations. | Can widen geographic and demographic reach, useful for rare-disease/dispersed populations — but depends on participant internet access and tech comfort. |
| IRB/ethics review focus | Reviews procedures occurring within one site's physical and staffing environment. | Additionally evaluates delegation to remote/local providers, eConsent comprehension safeguards, and remote safety monitoring. |
| Monitoring approach | In-person source data verification during scheduled site monitoring visits, tracked via CTMS. | Adds remote monitoring, wearable/digital-health data streams, and eCOA reconciliation against endpoints — typically needs a risk-based monitoring plan. |
| Best-fit trial characteristics | Complex procedures, in-clinic-only administration, intensive acute monitoring, first-in-human dosing. | Simple, well-characterized administration; low acute-risk profile; procedures a participant or local provider can safely perform. |
Common questions
FAQ
Can a trial mix centralized and decentralized elements?+
Yes — this is the norm rather than the exception. FDA's guidance treats decentralization as a set of elements that can be layered onto specific protocol procedures rather than a wholesale alternative design; most real-world DCTs are hybrids.
Does running a decentralized trial require separate FDA approval?+
No. DCTs operate under the same IND/IDE and GCP framework as centralized trials. FDA's September 2024 final guidance explains how to apply existing requirements when specific activities occur away from a traditional site — it does not create a separate DCT regulatory pathway.
Which model is cheaper?+
It depends on the protocol and population. Decentralized elements can reduce physical-site costs and travel-related dropout, but add technology, logistics, and vendor-oversight costs. The comparison has to be made procedure by procedure, not assumed in either direction.
Is a decentralized model appropriate for every therapeutic area?+
No. Trials involving complex procedures, in-clinic-only administration, or intensive acute monitoring generally remain centralized for those specific visits, even within an otherwise hybrid design.
